Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab + FOLFIRI versus cetuximab/bevacizumab + FOLFIRI in previously treated RAS/BRAF wild-type metastatic colorectal cancer
CTR20244425Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of amivantamab, sponsored by Janssen Pharmaceutical. Started Feb 2025; status: active.
02
Drugs
amivantamab
Beyond the preview
Go deeper on CTR20244425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244425.